Amylose resistant starch (HAM‐RS2) supplementation increases the proportion of <i>Faecalibacterium</i> bacteria in end‐stage renal disease patients: Microbial analysis from a randomized placebo‐controlled trial

Abstract

Supplementation of amylose resistant starch, HAM-RS2, in patients with CKD led to an elevation in Faecalibacterium and decrease in systemic inflammation. Microbial manipulation in CKD patients by using the prebiotic fiber may exert an anti-inflammatory effect through an elevation in the bacterial genera Faecalibacterium.